Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis
Kate Farms Inc · with Seattle Children's Hospital · NCT07234825
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 1–21 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 36
- US sites recruiting
- 1
- Study start
- March 18, 2026
- Record last updated
- April 16, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study aims to introduce a new dietary therapy for Eosinophilic Esophagitis (EoE) patients by using partial enteral nutrition (PEN) to enhance remission rates and explore how this approach affects immune function, gut microbiota, and environmental toxin exposures.
Being studied: Partial enteral nutrition (PEN) with dairy elimination; Dairy elimination alone
Conditions: Eosinophilic Esophagitis (EoE)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Pediatric patients 1 year to 21 of age presenting with chronic symptoms of dysphagia, odynophagia, vomiting or heartburn, chronic abdominal pain, weight loss, picky eating, to outpatient gastroenterology clinic and are planning to undergo EGD for evaluation.
Exclusion Criteria
- Non-English-Speaking Subjects, adults unable to consent, wards of the state, pregnant women, and prisoners will be excluded from the study.
- Patients with autoimmune conditions such as inflammatory bowel disease. Patients with prior esophageal or intestinal surgeries.
- Patients with history of eating disorders or ARFID.
- Patients with fistulizing or fibrotic disease on baseline EGD.
- Patients who have received proton pump inhibitory therapy in the past month.
Recruiting US locations
Seattle Children's Hospital
Seattle, WA 98105
Site contact: Elizabeth Reznikov, DO, PhD · 206-987-1062 · Elizabeth.Reznikov@seattlechildrens.org
Study contacts (from the official record)
- Danny Gagucas · 206-987-1062 · Danny.Gagucas@seattlechildrens.org
Similar studies in Washington
All nutrition & metabolism studies in Washington →- RecruitingHealthy volunteers
Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
ContextVision AB
- Location
- Seattle, WA
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
GlaxoSmithKline
- Location
- Seattle, WA + 46 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
GlaxoSmithKline
- Location
- Seattle, WA + 62 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure
SterileCare Inc.
- Location
- Seattle, WA + 6 other US sites
- Eligibility basics
- Ages 1 mo–18